Medically reviewed by Dr. Rao Khurram Ayoub, RPh, PhD (Pharmaceutics)
Written by Dr. Muhammad Imran, M.Phil, PharmD, BSc
Updated on
📋 When to Use
▼Use this calculator when switching a patient from one systemic glucocorticoid to another. It provides an equivalent dose of the target steroid.
Common indications:
- Formulation changes – oral ↔ intravenous access
- Therapy adjustments – side effects, availability, pregnancy, comorbidities
- Duration switching – short-acting ↔ long-acting for chronic disease or adrenal axis testing
- Care transitions – hospital admission, discharge, transfer
Reminder: This calculator provides equivalent dosing only. For acute illness/procedure in chronic steroid users → consider stress dosing.
💎 Insights & Cautions
▼⏱️ Duration of action – clinical relevance
- Short-acting (8–12h): cortisone, hydrocortisone → 2–3 divided doses/day
- Medium-acting (12–36h): methylprednisolone, prednisolone, prednisone, triamcinolone → once daily
- Long-acting (36–72h): betamethasone, dexamethasone → once daily
💧 Mineralocorticoid activity (adrenal insufficiency)
- Negligible: betamethasone, dexamethasone, triamcinolone, methylprednisolone
- Modest: hydrocortisone, cortisone, prednisolone, prednisone
Other: CYP inducers/inhibitors, severe liver/kidney disease can alter metabolism. Use only listed steroids.
❓ Why Use
▼Steroids differ in potency, duration, and mineralocorticoid effects. Unstandardized conversions risk serious harm:
- Under-treatment → adrenal insufficiency, hypotension, crisis
- Over-treatment → osteoporosis, hyperglycemia, immunosuppression, Cushingoid features
This calculator uses evidence-based glucocorticoid equivalency ratios (hydrocortisone=1, prednisone=4, dexamethasone=25) to minimize errors and improve safety during hospital transitions, shortages, or steroid changes.
Clinical context: For chronic supraphysiologic doses, educate about adrenal suppression and stress-dosing (2–3x usual dose during acute illness/surgery).
- Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ. 2021 Jul 12;374:n1380. https://doi.org/10.1136/bmj.n1380
- Beuschlein F, et al. Clinical Practice Guidelines for Glucocorticoid-Induced Adrenal Insufficiency. European Journal of Endocrinology & J Clin Endocrinol Metab. 2024. https://www.endocrine.org/clinical-practice-guidelines/glucocorticoid-induced-adrenal-insufficiency
- National Institute for Health and Care Excellence (NICE). Adrenal suppression: recognition and management. NICE Guideline [NG171]. 2020. https://www.ncbi.nlm.nih.gov/books/NBK279047/
- VUMC Internal Medicine. Steroid Conversion Chart. Vim Book Residency Handbook. 2025. https://vimbook.vumc.org/endocrinology/steroid-conversion
Corticosteroid Potency & Equivalence
| Corticosteroid | Equivalent Dose (mg) | Anti-inflammatory Potency | Duration of Action (hrs) | Mineralocorticoid Activity |
|---|---|---|---|---|
| Short-Acting | ||||
| Hydrocortisone | 20 | 1 | 8-12 | Moderate |
| Cortisone | 25 | 0.8 | 8-12 | Moderate |
| Intermediate-Acting | ||||
| Prednisone | 5 | 4 | 12-36 | Mild |
| Prednisolone | 5 | 4 | 12-36 | Mild |
| Methylprednisolone | 4 | 5 | 12-36 | Very Low |
| Triamcinolone | 4 | 5 | 12-36 | Very Low |
| Long-Acting | ||||
| Dexamethasone | 0.75 | 25-30 | 36-54 | None |
| Betamethasone | 0.6-0.75 | 25-30 | 36-54 | None |
Reference: Data compiled from UpToDate, Endotext, and NIH (PMC7896825, PMC10487400) [citation:3][citation:4][citation:7].
Clinical Decision Support Disclaimer
For Professional Use Only: This corticosteroid equivalence matrix is an educational tool designed to assist qualified healthcare professionals. It does not replace independent clinical judgment, formal institutional protocols, or diagnostic verification.
Variable Pharmacokinetics: Equivalence ratios are approximations derived from standardized clinical literature. Individual patient factors—including renal/hepatic clearance variations, metabolic differences, and drug-drug interactions—can significantly impact systemic corticosteroid potencies.
Always verify calculated maintenance schedules, tapering profiles, and cross-sensitivity risks against current official manufacturer prescribing information prior to therapy initiation.